Aralez Pharmaceuticals developed VIMOVO® with AstraZeneca AB. VIMOVO has been approved by the FDA for relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drug-associated gastric ulcers. Co.'s PA product candidates contain a combination of a proton pump inhibitor and enteric coated aspirin in a single tablet. Co.'s product candidates include PA32540 for the secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, and PA8140, a low dose version of PA32540. We show 24 historical shares outstanding datapoints in our ARLZ shares outstanding history coverage, used to compute ARLZ market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ARLZ market cap history over the course of time is important for investors
interested in comparing ARLZ's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ARLZ versus a peer is one thing; comparing
ARLZ market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ARLZ can fluctuate over the course of history.
With this page we aim to empower investors researching ARLZ by allowing them to research the ARLZ market cap history. |
Free ARLZ Email Alerts:
Video: The Importance of Market Cap
